Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support

It was the objective of this study to evaluate the efficacy and toxicity of an empirical antibiotic therapy consisting in ceftazidime and a glycopeptide antibiotic. All patients enrolled in the study had hematological malignancies and underwent high-dose therapy with peripheral blood stem cell (PBSC...

Full description

Saved in:
Bibliographic Details
Main Authors: Egerer, Gerlinde (Author) , Goldschmidt, Hartmut (Author) , Streich, Nikolaus (Author) , Ehrhard, Ingrid (Author) , Sonntag, Hans-Günther (Author) , Haas, Rainer (Author)
Format: Article (Journal)
Language:English
Published: 1999
In: Supportive care in cancer
Year: 1999, Volume: 7, Issue: 5, Pages: 336-342
ISSN:1433-7339
DOI:10.1007/s005200050272
Online Access:Verlag, lizenzpflichtig, Volltext: https://dx.doi.org/10.1007/s005200050272
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s005200050272
Get full text
Author Notes:G. Egerer, H. Goldschmidt, N. Streich, I. Ehrhard, H.G. Sonntag & R. Haas

MARC

LEADER 00000caa a22000002c 4500
001 1753625831
003 DE-627
005 20220819161515.0
007 cr uuu---uuuuu
008 210412s1999 xx |||||o 00| ||eng c
024 7 |a 10.1007/s005200050272  |2 doi 
035 |a (DE-627)1753625831 
035 |a (DE-599)KXP1753625831 
035 |a (OCoLC)1341404047 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Egerer, Gerlinde  |e VerfasserIn  |0 (DE-588)105502168X  |0 (DE-627)792516745  |0 (DE-576)167430882  |4 aut 
245 1 0 |a Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support  |c G. Egerer, H. Goldschmidt, N. Streich, I. Ehrhard, H.G. Sonntag & R. Haas 
264 1 |c 1999 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.04.2021 
520 |a It was the objective of this study to evaluate the efficacy and toxicity of an empirical antibiotic therapy consisting in ceftazidime and a glycopeptide antibiotic. All patients enrolled in the study had hematological malignancies and underwent high-dose therapy with peripheral blood stem cell (PBSC) support. In this retrospective study, 183 of 207 patients who had received a PBSC-supported high-dose therapy were evaluable. Any patients who had fever higher than 38.5°C received ceftazidime in combination with vancomycin (105 patients) or teicoplanin (69 patients). In 80 of 174 patients with fever (45%) the fever resolved within 72 h as a result of the treatment with ceftazidime and the glycopeptide antibiotic. In nonresponding patients, the changes included the replacement of ceftazidime by imipenem/cilastin (94 patients) and the addition of erythromycin (12 patients) or metronidazole (3 patients). Amphotericin B was administered in 29 patients. Following hematological reconstitution, the fever and clinical signs, including radiographic findings, resolved in 20 primarily nonresponding patients. In blood cultures, a significantly higher incidence of gram-positive than of gram-negative bacteria was observed (26 vs 7). The toxicity of the first-line antibiotic therapy was limited to allergic skin reactions in 12 patients. Ceftazidime in combination with a glycopeptide antibiotic provides an effective and safe first-line therapy for patients with neutropenic fever following PBSC-supported high-dose therapy. 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Streich, Nikolaus  |d 1971-  |e VerfasserIn  |0 (DE-588)123028485  |0 (DE-627)706133331  |0 (DE-576)293526397  |4 aut 
700 1 |a Ehrhard, Ingrid  |e VerfasserIn  |0 (DE-588)1077385323  |0 (DE-627)83645149X  |0 (DE-576)16830998X  |4 aut 
700 1 |a Sonntag, Hans-Günther  |d 1938-2024  |e VerfasserIn  |0 (DE-588)171318293  |0 (DE-627)061506826  |0 (DE-576)132120933  |4 aut 
700 1 |a Haas, Rainer  |d 1955-  |e VerfasserIn  |0 (DE-588)173773524  |0 (DE-627)698678141  |0 (DE-576)134613805  |4 aut 
773 0 8 |i Enthalten in  |t Supportive care in cancer  |d Berlin : Springer, 1993  |g 7(1999), 5, Seite 336-342  |h Online-Ressource  |w (DE-627)254909574  |w (DE-600)1463166-0  |w (DE-576)074754076  |x 1433-7339  |7 nnas  |a Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support 
773 1 8 |g volume:7  |g year:1999  |g number:5  |g pages:336-342  |g extent:7  |a Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support 
856 4 0 |u https://dx.doi.org/10.1007/s005200050272  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s005200050272  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210412 
993 |a Article 
994 |a 1999 
998 |g 173773524  |a Haas, Rainer  |m 173773524:Haas, Rainer  |d 910000  |d 910100  |e 910000PH173773524  |e 910100PH173773524  |k 0/910000/  |k 1/910000/910100/  |p 6  |y j 
998 |g 171318293  |a Sonntag, Hans-Günther  |m 171318293:Sonntag, Hans-Günther  |d 910000  |d 911700  |e 910000PS171318293  |e 911700PS171318293  |k 0/910000/  |k 1/910000/911700/  |p 5 
998 |g 1077385323  |a Ehrhard, Ingrid  |m 1077385323:Ehrhard, Ingrid  |d 910000  |d 911700  |e 910000PE1077385323  |e 911700PE1077385323  |k 0/910000/  |k 1/910000/911700/  |p 4 
998 |g 123028485  |a Streich, Nikolaus  |m 123028485:Streich, Nikolaus  |d 50000  |e 50000PS123028485  |k 0/50000/  |p 3 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 105502168X  |a Egerer, Gerlinde  |m 105502168X:Egerer, Gerlinde  |d 910000  |d 910100  |e 910000PE105502168X  |e 910100PE105502168X  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1753625831  |e 3906104605 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Egerer, Gerlinde","roleDisplay":"VerfasserIn","role":"aut","family":"Egerer","given":"Gerlinde"},{"role":"aut","display":"Goldschmidt, Hartmut","roleDisplay":"VerfasserIn","given":"Hartmut","family":"Goldschmidt"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Streich, Nikolaus","given":"Nikolaus","family":"Streich"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Ehrhard, Ingrid","given":"Ingrid","family":"Ehrhard"},{"display":"Sonntag, Hans-Günther","roleDisplay":"VerfasserIn","role":"aut","family":"Sonntag","given":"Hans-Günther"},{"display":"Haas, Rainer","roleDisplay":"VerfasserIn","role":"aut","family":"Haas","given":"Rainer"}],"title":[{"title":"Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support","title_sort":"Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 12.04.2021"],"language":["eng"],"recId":"1753625831","name":{"displayForm":["G. Egerer, H. Goldschmidt, N. Streich, I. Ehrhard, H.G. Sonntag & R. Haas"]},"origin":[{"dateIssuedKey":"1999","dateIssuedDisp":"1999"}],"id":{"eki":["1753625831"],"doi":["10.1007/s005200050272"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"title":[{"subtitle":"official journal of the Multinational Association of Supportive Care in Cancer","title":"Supportive care in cancer","title_sort":"Supportive care in cancer"}],"recId":"254909574","language":["eng"],"note":["Gesehen am 06.12.05"],"disp":"Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell supportSupportive care in cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"1999","pages":"336-342","issue":"5","volume":"7","text":"7(1999), 5, Seite 336-342","extent":"7"},"pubHistory":["1.1993 -"],"id":{"issn":["1433-7339"],"eki":["254909574"],"zdb":["1463166-0"]},"origin":[{"dateIssuedDisp":"1993-","dateIssuedKey":"1993","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg ; New York,NY"}],"physDesc":[{"extent":"Online-Ressource"}]}]} 
SRT |a EGERERGERLCEFTAZIDIM1999